Leuchter and coauthors conducted a randomized trial to determine if there is an association between early high-dose recombinant human erythropoietin treatment in preterm infants and biomarkers of encephalopathy of prematurity on magnetic resonance imaging (MRI) at term-equivalent age.
This randomized clinical trial assesses whether prophylactic early high-dose recombinant human erythropoietin (rhEPO) improves neurodevelopmental outcome for preterm infants at 2 years’ corrected age.
This systematic review to support the 2016 update of the US Preventive Services Task Force Recommendation Statement on lipid screening in childhood and adolescence for detection of multifactorial dyslipidemia summarizes published evidence about the benefits and harms of screening.
The US Burden of Disease Collaborators used a systematic analysis of descriptive epidemiology of diseases and injuries, their sequelae, and risk factors or clusters of risk factors from 1990 to 2010 to describe the health status of the United States. In an editorial, Fineberg discusses the health of the US population.
Lincoff and coauthors determine whether addition of aleglitazar to standard medical therapy reduces cardiovascular morbidity and mortality among 7226 patients with type 2 diabetes mellitus (T2D) and a recent acute coronary syndrome (ACS).
This meta-analysis summarizes the comparative effects of mortality and BPD ventilation strategies delivered within 24 hours of birth to neonates younger than 33 weeks’ gestational age who had not been intubated.
This study compares health care costs and outcomes for patients with joint replacement or sepsis before and after implementation of a value-drive outcomes program designed to give physicians information about clinical outcomes, costs, and variation.
This cohort study uses Netherlands Cancer Registry data to compare the long-term risk of breast cancer among subfertile women treated with ovarian stimulation and in vitro fertilization (IVF) vs non-IVF treatment between 1980 and 1995.
To determine the effects of secretory phospholipase A2 inhibition with varespladib on cardiovascular outcomes, Nicholls and coauthors randomized 5145 patients within 96 hours of presentation of an acute coronary syndrome to either varspladib (n = 2572) or placebo (n = 2573) for 16 weeks.
This randomized clinical trial compares the effects of hydrocortisone vs placebo on development of septic shock among intensive care patients with severe sepsis who were not in septic shock.
In a randomized controlled superiority trial involving 13 229 patients with non–ST-segment elevation acute coronary syndromes undergoing early planned invasive strategies, Steg and coauthors compared otamixaban, an intravenous direct factor Xa inhibitor, with unfractionated heparin plus eptifibatide to achieve optimal anticoagulation.